Sign up to save your podcasts
Or
Share Breaking News: SOL-1 Superiority Data for Axpaxli in Wet AMD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Breaking News: SOL-1 Superiority Data for Axpaxli in Wet AMD
Hosts:
John Kitchens, MD
Scott Krzywonos
Show Summary:
In this emergency episode of RetinUp, John and Scott break down the newly announced SOL-1 study data evaluating Axpaxli (Ocular Therapeutix) for the treatment of wet AMD.
The superiority trial compared a single Axpaxli injection to a single Eylea injection (after all eyes received a pair of monthly Eylea doses) in patients with wet AMD. The primary endpoint was the proportion of patients maintaining vision at 36 weeks (defined as losing fewer than 15 ETDRS letters).
Key findings include:
- 74% of Axpaxli patients maintained vision at 36 weeks vs. 59% in the Eylea arm
- Approximately 75% of Axpaxli patients required no rescue treatment through 36 weeks
- Durable disease control extending 24–36 weeks, with some patients reaching 52 weeks
John and Scott discuss:
- How the SOL-1 study design (FDA-aligned superiority endpoint) shaped the results
- What this means for durability beyond traditional anti-VEGF therapies
- Why the market reaction diverged from clinical enthusiasm
- How to talk to your patients who hear about study data
- What to expect next from the SOL-R study and a potential FDA submission
Why It Matters:
For the first time in years, retina specialists may be looking at a new mechanism of action — a tyrosine kinase inhibitor — with the potential to significantly extend treatment intervals after a single injection.
More detailed analysis and expert commentary coming soon on RetinUp.
Listen & Subscribe:
RetinUp.com | Apple Podcasts | Spotify | YouTube
Credits:
Production & Marketing: Laura Brown
Business Operations: Liz Hogan
View all episodes
By RetinUp Podcast, LLCHosts:
John Kitchens, MD
Scott Krzywonos
Show Summary:
In this emergency episode of RetinUp, John and Scott break down the newly announced SOL-1 study data evaluating Axpaxli (Ocular Therapeutix) for the treatment of wet AMD.
The superiority trial compared a single Axpaxli injection to a single Eylea injection (after all eyes received a pair of monthly Eylea doses) in patients with wet AMD. The primary endpoint was the proportion of patients maintaining vision at 36 weeks (defined as losing fewer than 15 ETDRS letters).
Key findings include:
- 74% of Axpaxli patients maintained vision at 36 weeks vs. 59% in the Eylea arm
- Approximately 75% of Axpaxli patients required no rescue treatment through 36 weeks
- Durable disease control extending 24–36 weeks, with some patients reaching 52 weeks
John and Scott discuss:
- How the SOL-1 study design (FDA-aligned superiority endpoint) shaped the results
- What this means for durability beyond traditional anti-VEGF therapies
- Why the market reaction diverged from clinical enthusiasm
- How to talk to your patients who hear about study data
- What to expect next from the SOL-R study and a potential FDA submission
Why It Matters:
For the first time in years, retina specialists may be looking at a new mechanism of action — a tyrosine kinase inhibitor — with the potential to significantly extend treatment intervals after a single injection.
More detailed analysis and expert commentary coming soon on RetinUp.
Listen & Subscribe:
RetinUp.com | Apple Podcasts | Spotify | YouTube
Credits:
Production & Marketing: Laura Brown
Business Operations: Liz Hogan